StockUS listing USCASBFPINKHealthcareProfitless Growth

CanSino Biologics Inc(CASBF) Stock Analysis | Healthcare

USD --+0.00%
Reward46Moderate
Risk64Medium-High
75%Data
Thin 3% profit margin · Revenue growing 34% YoY
USD —+0.00 (+0.00%) Previous close · PINK
Market cap 953.59M
Reward Ratingⓘ46 Moderate reward assessment · 75% data coverage
Bottom 25% of stocksView factors
Risk Ratingⓘ64 Medium-High risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on CASBF to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is CanSino Biologics Inc?

develops, manufactures, and commercializes vaccines in the People's Republic of China.

AI Brief Pro

The brief on CanSino Biologics Inc

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is CanSino Biologics Inc?

develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 953.59M, and a P/E ratio of 193.0x.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Moderate volatility with meaningful macro and earnings sensitivity.
Valuation
Premium valuation reflects strong growth expectations already priced in.

OpenBook Logo Analysis

Reward: Moderate (46)

Similar stocks to compare

A short list of Drug Manufacturers - Specialty & Generic names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Market Cap953.59M
Beta1.278
Insider Activity
12M windowNo data
No insider activity data available for this ticker.